COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED MODRAK ET AL.

PHARMACOLOGICAL ATTENUATION OF ELECTRICAL EFFECTS IN A MODEL OF COMPRESSION NEUROPATHY http://dx.doi.org/10.2106/JBJS.18.00162

Page 1

Appendix

Tissue Harvest for Histological Analysis and Blinding

Animals were killed at random, and tissue was harvested for histomorphometric analyses by blinded investigators after compression (day 0) and at 7 and 15 days after decompression. In the experiments, the mice were identified by a number assigned on the day of the nerve surgery and were not identified by treatment group except for dosing. Treatment (EPO, 4-AP, or saline solution) was administered daily as indicated by the protocol in an unblinded fashion by one investigator (or a pair to cover odd days and weekends). During that unblinded period to provide dosing, no data were acquired or analyzed. The animals underwent functional assessment (walking) just before dosing, and footprints were indexed by mouse number and date only. The tissue was harvested by number by another investigator, and the histological specimens were sent to the Center for Musculoskeletal Research Histology Core Facility (for standard histological analysis) and the Electron Microscopy Facility for toluidine-blue-based histomorphometric analysis. The slides were associated with the mouse number, and the analysis was done on the basis of the number alone. In this way, the animals were only identified by their treatment group in two instances: first, for treatment by an investigator who was not performing any analysis and, second, after the analysis was completed for tabulation of metrics. Harvested tissues were placed into 0.1-M sodium-cacodylate-buffered 4.0% paraformaldehyde/2.5-glutaraldehyde at 4°C for 48 hours, postfixed for 2 hours in darkness with 1.0% osmium tetroxide/1.5% potassium ferrocyanide, and dehydrated (30-minute exchanges) in graded ethanol to 100% (×3), 100% propylene oxide (×2), 1:1 propylene-oxide/EPON-Araldite resin, and 100% EPON-Araldite resin (60 minutes, and then in fresh resin overnight). Samples were then entered into resin-filled silicone molds and polymerized (48 hours, 65°C). One-micrometer sections in water droplets on glass slides were heated on hotplates and stained with 0.1% toluidine blue.

Copyright @ by The Journal of Bone and Joint Surgery, Incorporated Modrak et al.

 $Pharmacological\ Attenuation\ of\ Electrical\ Effects\ in\ a\ Model\ of\ Compression\ Neuropathy\ http://dx.doi.org/10.2106/JBJS.18.00162$

Page 2

TABLE E-1 Significant P Values for Figure 1

	P Value*					
Time	EPO/EPO	4-AP/4-AP				
Baseline	NS	NS				
Week 1	0.0107	0.0003				
Week 2	0.0007	< 0.0001				
Week 3	< 0.0001	< 0.0001				
Week 4	0.0018	< 0.0001				
Week 5	0.0002	< 0.0001				
Week 6	< 0.0001	< 0.0001				

^{*}Compared with untreated group. NS = not significant.

Copyright @ by The Journal of Bone and Joint Surgery, Incorporated Modrak et al.

 $Pharmacological\ Attenuation\ of\ Electrical\ Effects\ in\ a\ Model\ of\ Compression\ Neuropathy\ http://dx.doi.org/10.2106/JBJS.18.00162$

Page 3

TABLE E-2 Significant P Values for Figure 2

	P Value*			
Parameter	Sham	EPO/EPO	4-AP/4-AP	
Axon diameter	< 0.0001	NS	NS	
Fiber diameter	< 0.0001	NS	NS	
G ratio	NS	NS	< 0.0001	
Myelin thickness	< 0.0001	NS	< 0.0001	
No. of myelinated fibers	< 0.0001	< 0.0001	NS	
Proportion of myelinated fibers				
Small fibers	Measurement not performed	NS	NS	
Medium fibers	Measurement not performed	0.0488	0.0111	
Large fibers	Measurement not performed	0.0016	0.0193	

^{*}Compared with untreated group. NS = not significant.

Copyright $\ensuremath{\mathbb{O}}$ by The Journal of Bone and Joint Surgery, Incorporated

Modrak et al.

 $Pharmacological\ Attenuation\ of\ Electrical\ Effects\ in\ a\ Model\ of\ Compression\ Neuropathy\ http://dx.doi.org/10.2106/JBJS.18.00162$

Page 4

TABLE E-3 Significant P Values for Figure 3

	P Value*				
Time	Saline/EPO	EPO/EPO	Saline/4-AP	4-AP/4-AP	
Day 0	NS	< 0.0001	NS	< 0.0001	
Day 3	NS	< 0.0001	0.0011	< 0.0001	
Day 5	0.0218	< 0.0001	< 0.0001	< 0.0001	
Day 7	0.0012	< 0.0001	< 0.0001	< 0.0001	
Day 9	0.0001		< 0.0001	< 0.0001	
Day 11	0.0326	Measurement not performed	Measurement not performed	Measurement not performed	

^{*}Compared with untreated group. NS = not significant.

Copyright @ by The Journal of Bone and Joint Surgery, Incorporated Modrak et al.

 $Pharmacological\ Attenuation\ of\ Electrical\ Effects\ in\ a\ Model\ of\ Compression\ Neuropathy\ http://dx.doi.org/10.2106/JBJS.18.00162$

Page 5

TABLE E-4 Significant P Values for Figure 4

	P Value*				
Parameter	Sham	Saline/EPO	EPO/EPO	Saline/4-AP	4-AP/4-AP
Axon diameter	<0.0001	< 0.0001	< 0.0001	< 0.0001	0.0003
Fiber diameter	<0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
G ratio	NS	< 0.0001	NS	< 0.0001	< 0.0001
Myelin thickness	<0.0001	0.0002	< 0.0001	< 0.0001	< 0.0001
No. of myelinated	0.0006	NS	< 0.0001	NS	NS
fibers					
Proportion of					
myelinated fibers					
Small fibers	Measurement	< 0.0001	< 0.0001	0.0434	0.0455
	not performed				
Medium fibers	Measurement	0.0005	0.0424	NS	0.0251
	not performed				
Large fibers	Measurement	< 0.0001	< 0.0001	0.0005	0.0001
	not performed				

^{*}Compared with untreated group. NS = not significant.

Copyright ${}^{\scriptsize{\textcircled{\tiny }}}$ by The Journal of Bone and Joint Surgery, Incorporated

Modrak et al.

 $Pharmacological\ Attenuation\ of\ Electrical\ Effects\ in\ a\ Model\ of\ Compression\ Neuropathy\ http://dx.doi.org/10.2106/JBJS.18.00162$

Page 6

TABLE E-5 Significant P Values for Figure 5

	P Value*				
Parameter	Sham	Saline/EPO	EPO/EPO	Saline/4-AP	4-AP/4-AP
Axon diameter	0.0180	NS	NS	0.0107	NS
Fiber diameter	0.0028	NS	0.0320	< 0.0001	NS
G ratio	NS	NS	NS	< 0.0001	< 0.0001
Myelin thickness	0.0029	NS	0.0290	< 0.0001	< 0.0001
No. of myelinated fibers	NS	NS	NS	NS	NS
Proportion of myelinated fibers					
Small fibers	Measurement not performed	NS	NS	NS	NS
Medium fibers	Measurement not performed	NS	NS	<0.0001	0.0044
Large fibers	Measurement not performed	NS	0.0121	0.0001	0.0332

^{*}Compared with untreated group. NS = not significant.